Difference between revisions of "Alemtuzumab (Campath)"
Jump to navigation
Jump to search
m |
m |
||
| Line 9: | Line 9: | ||
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
*[[Myelodysplastic syndrome]] | *[[Myelodysplastic syndrome]] | ||
| + | *[[Waldenström macroglobulinemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 16: | Line 17: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *5/7/2001: Initial approval "for the treatment of patients with [[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | B-cell chronic lymphocytic leukemia]] who have been treated with [ | + | *5/7/2001: Initial approval "for the treatment of patients with [[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | B-cell chronic lymphocytic leukemia]] who have been treated with [[:Category:Alkylating_agents|alkylating agents]] and who have failed [[Fludarabine (Fludara) | fludarabine]] therapy."<ref>[http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/alemmil050701L.htm FDA approval letter dated May 7th, 2001]</ref> |
*9/19/2007: Indication expanded "to include use as a single agent for treatment of [[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | B-cell chronic lymphocytic leukemia (B-CLL)]]" | *9/19/2007: Indication expanded "to include use as a single agent for treatment of [[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | B-cell chronic lymphocytic leukemia (B-CLL)]]" | ||
*October 2012: Genzyme withdraws drug from USA and EU (still available for B-CLL patients, however). See Lancet editorial.<ref>[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61776-0/fulltext Alemtuzumab for multiple sclerosis]</ref> | *October 2012: Genzyme withdraws drug from USA and EU (still available for B-CLL patients, however). See Lancet editorial.<ref>[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61776-0/fulltext Alemtuzumab for multiple sclerosis]</ref> | ||
| Line 30: | Line 31: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Intravenous chemotherapy]] | ||
| + | |||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
| + | [[Category:Anti-CD52 antibodies]] | ||
| + | |||
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
[[Category:Myelodysplastic syndrome medications]] | [[Category:Myelodysplastic syndrome medications]] | ||
| + | [[Category:Waldenström macroglobulinemia medications]] | ||
| + | |||
[[Category:Drugs FDA approved in 2001]] | [[Category:Drugs FDA approved in 2001]] | ||
Revision as of 20:46, 20 November 2014
General information
Class/mechanism: Anti-CD52 antibody that is believed to cause antibody-dependent cell-mediated cytotoxicity of cells that express the CD52 antigen on their surface: B and T lymphocytes, most monocytes, macrophages, natural killer (NK) cells, and a subpopulation of granulocytes.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Myelodysplastic syndrome
- Waldenström macroglobulinemia
Patient drug information
- Alemtuzumab (Campath) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found at the end of page 2 of the Alemtuzumab (Campath) package insert[1]
- Alemtuzumab (Campath) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 5/7/2001: Initial approval "for the treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy."[6]
- 9/19/2007: Indication expanded "to include use as a single agent for treatment of B-cell chronic lymphocytic leukemia (B-CLL)"
- October 2012: Genzyme withdraws drug from USA and EU (still available for B-CLL patients, however). See Lancet editorial.[7]
Also known as
Precise Name: alemtuzumab (RXCUI 117055)
Campath, Campath-1H, Lemtrada, Mabcampath
References
- ↑ 1.0 1.1 1.2 Alemtuzumab (Campath) package insert
- ↑ Alemtuzumab (Campath) package insert (locally hosted backup)
- ↑ Campath manufacturer's website
- ↑ Alemtuzumab (Campath) patient drug information (Chemocare)
- ↑ Alemtuzumab (Campath) patient drug information (UpToDate)
- ↑ FDA approval letter dated May 7th, 2001
- ↑ Alemtuzumab for multiple sclerosis